These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The use of moxalactam in the treatment of serious infections due to multi-resistant organisms. Srinivasan S; Francke EL; Ortiz-Neu C; Prince AS; Neu HC Infection; 1983; 11(6):291-5. PubMed ID: 6668067 [TBL] [Abstract][Full Text] [Related]
3. Moxalactam therapy for bacterial infections. Winston DJ; Busuttil RW; Kurtz TO; Young LS Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of latamoxef in neonates]. Iwai N; Sasaki A; Taneda Y; Mizoguchi F; Nakamura H; Tauchi N; Kawamura M; Ozaki T Jpn J Antibiot; 1983 Sep; 36(9):2336-48. PubMed ID: 6655852 [TBL] [Abstract][Full Text] [Related]
7. Imipenem versus moxalactam in the treatment of serious infections. Eron LJ; Hixon DL; Park CH; Goldenberg RI; Poretz DM Antimicrob Agents Chemother; 1983 Dec; 24(6):841-6. PubMed ID: 6581755 [TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacokinetic evaluation of parenteral moxalactam in infants and children. Keyserling H; Feldman WE; Moffitt S; Manning N; Hollins M Antimicrob Agents Chemother; 1982 Jun; 21(6):898-901. PubMed ID: 6214210 [TBL] [Abstract][Full Text] [Related]
9. Moxalactam in the treatment of pediatric infections. Yogev R; Schreiber M; Gardner S; Shulman ST Am J Dis Child; 1982 Sep; 136(9):836-9. PubMed ID: 6214182 [TBL] [Abstract][Full Text] [Related]
10. Moxalactam therapy of difficult infections in patients with serious underlying conditions. Mogabgab WJ; Bauman DC; LaCorte WF; Pollock B; Pauling B; Beville RB; Holmes BJ J Int Med Res; 1983; 11(5):269-78. PubMed ID: 6642067 [TBL] [Abstract][Full Text] [Related]
11. Absorption, excretion, and clinical efficacy of moxalactam in pediatric patients. Fujii R Rev Infect Dis; 1982; 4 Suppl():S656-63. PubMed ID: 6218579 [TBL] [Abstract][Full Text] [Related]
12. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Carmine AA; Brogden RN; Heel RC; Romankiewicz JA; Speight TM; Avery GS Drugs; 1983 Oct; 26(4):279-333. PubMed ID: 6354685 [TBL] [Abstract][Full Text] [Related]
15. Once daily ceftriaxone for central nervous system infections and other serious pediatric infections. Yogev R; Shulman ST; Chadwick EG; Davis AT; Glogowski W Pediatr Infect Dis; 1986; 5(3):298-303. PubMed ID: 3725639 [TBL] [Abstract][Full Text] [Related]
16. [Clinical effect of latamoxef on newborn and premature infants]. Takimoto M; Oka T; Yoshioka H; Tsuchida A; Sanae N; Maruyama S Jpn J Antibiot; 1983 Sep; 36(9):2297-301. PubMed ID: 6655848 [TBL] [Abstract][Full Text] [Related]
17. In vitro and clinical evaluation of moxalactam. Tanphaichitra D; Srimuang S J Med Assoc Thai; 1986 Feb; 69(2):82-7. PubMed ID: 3711748 [No Abstract] [Full Text] [Related]
19. Clinical evaluation of moxalactam in the treatment of respiratory tract infections, hepatobiliary infections, and septicemia. Saito A Rev Infect Dis; 1982; 4 Suppl():S623-8. PubMed ID: 6218575 [TBL] [Abstract][Full Text] [Related]
20. Failure of moxalactam in the treatment of neonatal sepsis and meningitis from Salmonella typhimurium. Adler SP; Markowitz SM J Pediatr; 1983 Dec; 103(6):913-6. PubMed ID: 6358437 [No Abstract] [Full Text] [Related] [Next] [New Search]